annual meeting program - American Society of Clinical Oncology

SATURDAY
Saturday, June 5, 2010
Brd. 8 Phase I PK/PD study of RO5083945 (GA201), the first glycoengineered
anti-EGFR monoclonal antibody (mAb) with optimized antibody dependent
cellular cytotoxicity (ADCC). (Abstract #2522)
B. Markman, C. Gomez-Roca, A. Cervantes-Ruiperez, J. Delord, L. Paz Ares,
J. Soria, J. Corral, S. Hollingsworth, L. Manenti, J. Tabernero
Brd. 9 Radioimmunotherapy (RIT) with 131 l-L19SIP in solid cancers (SC) and
lymphoproliferative diseases: Final results of the first human trial. (Abstract
#2523)
G. Del Conte, P. A. Erba, A. Fasolo, C. Chiesa, C. Grana, H. Menssen, D. Neri,
G. Mariani, E. Bombardieri, L. Gianni
Brd. 10 First-in-human dose-escalation safety and PK trial of a novel intravenous
humanized monoclonal CovX body inhibiting angiopoietin 2. (Abstract
#2524)
L. S. Rosen, D. S. Mendelson, R. B. Cohen, M. S. Gordon, J. W. Goldman,
I. K. Bear, B. Byrnes, R. Perea, S. L. Schoenfeld, A. Gollerkeri
Brd. 11 Phase I study of SCH 900105 (SC), an anti-hepatocyte growth factor (HGF)
monoclonal antibody (MAb), as a single agent and in combination with
erlotinib (E) in patients (pts) with advanced solid tumors. (Abstract #2525)
A. Patnaik, G. J. Weiss, K. Papadopoulos, R. Tibes, A. W. Tolcher, F. C. Payumo,
M. M. Cotreau, J. Jac, R. Isaacs, R. K. Ramanathan
Brd. 12 Final reporting of a phase I clinical trial of the oral PPAR-gamma agonist,
CS-7017, in patients with advanced malignancies. (Abstract #2526)
M. J. Pishvaian, I. Cotarla, A. J. Wagner, J. F. Deeken, A. R. He, J. J. Hwang,
G. D. Demetri, A. Halim, C. Copigneaux, J. Marshall
Brd. 13 Phase I and pharmacokinetic (PK) study of eribulin (E7389) in patients (pts)
with renal dysfunction (RD) and advanced urothelial cancer (UC): A
California Cancer Consortium trial. (Abstract #2527)
T. W. Synold, D. D. Tsao-Wei, D. I. Quinn, S. G. Groshen, A. Aparicio,
P. Twardowski, W. M. Stadler, D. R. Gandara, P. Lara Jr., E. M. Newman,
California Cancer Consortium with Pittsburgh
Brd. 14 AUY922, a novel HSP90 inhibitor: Final results of a first-in-human study in
patients with advanced solid malignancies. (Abstract #2528)
T. A. Samuel, C. Sessa, C. Britten, K. S. Milligan, M. M. Mita, U. Banerji,
T. J. Pluard, P. Stiegler, C. Quadt, G. Shapiro
Brd. 15 A phase I dose-escalation study of the Hsp90 inhibitor STA-9090
administered once weekly in patients with solid tumors. (Abstract #2529)
J. W. Goldman, R. N. Raju, G. A. Gordon, V. M. Vukovic, R. Bradley, L. S. Rosen
Brd. 16 Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase
inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor
(IR) in patients with advanced solid tumors. (Abstract #2530)
C. P. Carden, E. S. Kim, R. L. Jones, S. M. Alam, F. M. Johnson, A. W. Stephens,
S. Poondru, R. Gedrich, S. M. Lippman, S. B. Kaye
Brd. 17 Phase I dose-escalation study of continuous oral dosing of OSI-906, a dual
tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and
insulin receptor (IR), in patients with advanced solid tumors. (Abstract #2531)
T. Evans, C. R. Lindsay, E. Chan, B. Tait, S. A. Michael, S. Day, A. W. Stephens,
A. Franke, S. Poondru, I. Puzanov
Brd. 18 Interim results of a phase I trial of intraventricular rituximab plus
methotrexate in recurrent CNS lymphoma: Macrophage polarization and
acquired resistance to therapy. (Abstract #2532)
J. L. Rubenstein, C. Kadoch, V. S. Wong, W. Hyun, C. Lowell
Brd. 19 A phase I study of celecoxib (C) and patupilone (EPO906) in patients (pts)
with metastatic colorectal cancer (mCRC). (Abstract #2533)
S. Iqbal, A. B. El-Khoueiry, D. Yang, S. Cole, W. Boswell, J. Shriki, Y. Ning,
R. D. Agafitei, X. Menendez, H. Lenz
122